Monthly Cumulative Number and Percent of Children <20 Months Who Received Nirsevimab by Age Group and Jurisdiction, United States

Monthly Cumulative Number and Percent of Children <20 Months Who Received Nirsevimab by Age Group and Jurisdiction • Estimated nirsevimab coverage for children 0-19 months is assessed through U.S. jurisdictions’ Immunization Information Systems (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group. • Starting in July 2023, the CDC recommended the RSV vaccine to protect against serious illness from RSV. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html)